siRNA-mediated silencing of CDK8 inhibits proliferation and growth in breast cancer cells [Retraction].
Authors: Abstract [This retracts the article on p. 92 in vol. 7, PMID: 24427329.]. PMID: 29874337 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - June 7, 2018 Category: Cancer & Oncology Tags: Int J Clin Exp Pathol Source Type: research

Risk, Risk Factors, and Surveillance of Subsequent Malignant Neoplasms in Survivors of Childhood Cancer: A Review.
Abstract Subsequent malignant neoplasms (SMNs) in childhood cancer survivors cause substantial morbidity and mortality. This review summarizes recent literature on SMN epidemiology, risk factors, surveillance, and interventions. Survivors of childhood cancer experience long-term increased SMN risk compared with the general population, with a greater than twofold increased solid tumor risk extending beyond age 40 years. There is a dose-dependent increased risk for solid tumors after radiotherapy, with the highest risks for tumors occurring in or near the treatment field (eg, greater than fivefold increased risk for...
Source: Clinical Breast Cancer - June 6, 2018 Category: Cancer & Oncology Authors: Turcotte LM, Neglia JP, Reulen RC, Ronckers CM, van Leeuwen FE, Morton LM, Hodgson DC, Yasui Y, Oeffinger KC, Henderson TO Tags: J Clin Oncol Source Type: research

Trastuzumab-induced cardiotoxicity and its risk factors in real-world setting of breast cancer patients.
JP Abstract PURPOSE: Cardiotoxicity is the most important side effect of trastuzumab treatment. Heart function monitoring is recommended during the treatment which has led to growing use of resources. The aim of this retrospective study was to determine the frequency and timing of trastuzumab cardiotoxicity and its risk factors in real-world setting. METHODS: Single institute, retrospective collection of data on HER2+ breast cancer patients (n = 246) was carried out through a pharmacy search for patients who had received trastuzumab in 2006-2014. Clinical and pathological factors, treatment his...
Source: Clinical Breast Cancer - June 5, 2018 Category: Cancer & Oncology Authors: Moilanen T, Jokimäki A, Tenhunen O, Koivunen JP Tags: J Cancer Res Clin Oncol Source Type: research

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.
lem G Abstract Purpose This phase III study evaluated ribociclib plus fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer who were treatment naïve or had received up to one line of prior endocrine therapy in the advanced setting. Patients and Methods Patients were randomly assigned at a two-to-one ratio to ribociclib plus fulvestrant or placebo plus fulvestrant. The primary end point was locally assessed progression-free survival. Secondary end points included overall survival, overall response rate, and safety. Results A total of 484...
Source: Clinical Breast Cancer - June 3, 2018 Category: Cancer & Oncology Authors: Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Vidam G, Wang Y, Rodriguez Lorenc K, Miller M, Taran T, Jerusalem G Tags: J Clin Oncol Source Type: research

Tamoxifen and the risk of Parkinsonism: a case/non-case study.
CONCLUSION: This study did not find evidence for Parkinsonism associated with tamoxifen. PMID: 29862427 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - June 3, 2018 Category: Cancer & Oncology Authors: Montastruc F, Khosrow-Khavar F, de Germay S, Renoux C, Rousseau V, Durrieu G, Montastruc M, Rascol O, Sommet A, Lapeyre-Mestre M, Benevent J, Montastruc JL Tags: Eur J Clin Pharmacol Source Type: research

Breast carcinoma in sclerosing adenosis: a clinicopathological and immunophenotypical analysis on 206 lesions.
Abstract AIMS: To fully elucidate the clinicopathological features of breast carcinoma in sclerosing adenosis (SA-BC). METHODS: Clinical and histological characteristics of 206 SA-BCs from 180 patients were retrospectively evaluated. Immunohistochemical phenotype was examined. The clinicopathological relevance of the topographical pattern of SA-BCs was analysed. RESULTS: Overall, up to 46 patients (25.6%) had contralateral cancer, either SA associated or not. Of 99 cases who underwent core needle biopsy (CNB), 36 were underestimated as adenosis or atypical ductal hyperplasia at CNB, 5 invasive cases were...
Source: Clinical Breast Cancer - June 1, 2018 Category: Cancer & Oncology Authors: Yu BH, Tang SX, Xu XL, Cheng YF, Bi R, Shui RH, Tu XY, Lu HF, Zhou XY, Yang WT Tags: J Clin Pathol Source Type: research

Use of antipsychotics and risk of breast cancer: A Danish nationwide case-control study.
CONCLUSIONS: Overall, our results do not suggest a clinically important association between antipsychotic use and risk of breast cancer. The importance of drug-induced prolactin elevation is unclear but may lead slightly increased risk of estrogen receptor positive breast cancer. PMID: 29858518 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - June 1, 2018 Category: Cancer & Oncology Authors: Pottegård A, Lash TL, Cronin-Fenton D, Ahern TP, Damkier P Tags: Br J Clin Pharmacol Source Type: research

Optimal timing for pegfilgrastim administration in Japanese breast cancer patients receiving intermediate-risk chemotherapies.
Abstract Background Pegfilgrastim is widely used for prophylaxis of febrile neutropenia (FN) in cancer patients receiving chemotherapies. However, the optimal timing of pegfilgrastim administration has not been established. Objective We investigated the effect of the timing of pegfilgrastim administration on the prevention of FN in patients with breast cancer undergoing intermediate-risk chemotherapies. Method We retrospectively analysed the incidence of FN in patients with breast cancer treated at our institution with intermediate-risk chemotherapies and primary or secondary prophylactic pegfilgrastim between 201...
Source: Clinical Breast Cancer - June 1, 2018 Category: Cancer & Oncology Authors: Hayama T, Sakurai K, Miura K, Washinosu S, Tsuboi S, Uchiike A, Yoshida Y, Takei M Tags: Int J Clin Pharm Source Type: research

Breast Carcinoma: Updates in Molecular Profiling 2018.
Abstract The most significant contribution of molecular subtyping of breast carcinomas has been the identification of estrogen-positive and estrogen-negative tumor subtypes. Knowledge of genetic alterations in these tumors will help clinicians identify novel therapeutic targets. Understanding the progression pathways involved in the transition of in situ carcinoma to invasive carcinoma might lead to efficient risk stratification in these patients. The Cancer Genome Analysis Network has collected genomic and epigenomic data to provide comprehensive information regarding carcinogenesis and pathway interactions....
Source: Clinical Breast Cancer - May 22, 2018 Category: Cancer & Oncology Authors: Bandyopadhyay S, Bluth MH, Ali-Fehmi R Tags: Clin Lab Med Source Type: research

Comprehensive Geriatric Assessment: Interprofessional Team Recommendations for Older Adult Women With Breast Cancer.
Abstract BACKGROUND: Geriatric oncology incorporates comprehensive geriatric assessment (CGA) and traditional oncology care. OBJECTIVES: The aims are to identify limitations reflected by mean scores on the CGA instruments and describe the CGA recommendations documented in the medical record. METHODS: CGA was administered and consisted of the Timed Up and Go Test, the Activities of Daily Living Scale, the Instrumental Activities of Daily Living Scale, grip strength, falls, pain, the Brief Fatigue Inventory, the Pittsburgh Sleep Quality Index, the Geriatric Depression Scale, the Mini-Cog, and the Mini Nutr...
Source: Clinical Breast Cancer - May 22, 2018 Category: Cancer & Oncology Authors: Overcash J Tags: Clin J Oncol Nurs Source Type: research

Previvor: An Oncology Nurse's Story of Cancer Risk Reduction Through Genetic Testing.
Abstract My mother was diagnosed with triple-negative breast cancer in 1998 at age 48. Her younger sister has been diagnosed with breast cancer at age 33 but ultimately died of ovarian cancer at age 47. Her mother died of ovarian cancer at age 47. I knew my fate. Meanwhile, as the medical world around me kept turning, the medical-surgical floor on which I worked became an oncology floor. This was not part of my plan. PMID: 29781468 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 22, 2018 Category: Cancer & Oncology Authors: Kelly J Tags: Clin J Oncol Nurs Source Type: research

Cognitive Changes: Educating Breast Cancer Survivors With the Think Well: Healthy Living to Improve Cognitive Function Program.
Abstract Cognitive changes may occur after cancer treatment and interfere with day-to-day activities of breast cancer survivors. Current guidelines recommend validating cognitive concerns, increasing patient education, and suggesting appropriate interventions. Educational programs, including Think Well: Healthy Living to Improve Cognitive Function, can increase the awareness of cognitive changes and provide strategies for self-management to breast cancer survivors and their family and friends. PMID: 29781472 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 22, 2018 Category: Cancer & Oncology Authors: Vo JB, Nolan TS, Bail JR, Gisiger-Camata S, Meneses K Tags: Clin J Oncol Nurs Source Type: research

Retraction Note to: The BRCA2 variant c.68-7  T  >  A is associated with breast cancer.
Retraction Note to: The BRCA2 variant c.68-7 T > A is associated with breast cancer. Hered Cancer Clin Pract. 2018;16:10 Authors: Møller P, Hovig E Abstract [This retracts the article DOI: 10.1186/s13053-017-0080-y.]. PMID: 29745381 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 12, 2018 Category: Cancer & Oncology Authors: Møller P, Hovig E Tags: Hered Cancer Clin Pract Source Type: research

Cancer in Pregnancy.
This article reviews some of the more common types of cancer that may be encountered during pregnancy. It reviews the unique challenges with the diagnosis and treatment of breast, cervical, hematologic, and colon cancers in pregnant patients. PMID: 29747725 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 12, 2018 Category: Cancer & Oncology Authors: McCormick A, Peterson E Tags: Obstet Gynecol Clin North Am Source Type: research

Hormone Therapy in Breast Cancer Survivors and Those at High Risk for Breast Cancer.
Abstract Women and health care providers are often fearful of using hormone therapy to deal with distressing menopausal symptoms in circumstances where there is a perceived or real increased risk of breast cancer. This paper examines the evidence for and against hormone therapy use in 3 common clinical situations: the woman with a positive family history in a first-degree relative, the woman who has undergone risk-reducing salpingo-oophorectomy due to a known genetic mutation, and the woman in whom treatment of breast cancer has induced premature menopause. PMID: 29750683 [PubMed - as supplied by publisher] (...
Source: Clinical Breast Cancer - May 10, 2018 Category: Cancer & Oncology Authors: Reid RL Tags: Clin Obstet Gynecol Source Type: research

SPIN1, negatively regulated by miR-148/152, enhances Adriamycin resistance via upregulating drug metabolizing enzymes and transporter in breast cancer.
CONCLUSIONS: Our results establish that SPIN1, negatively regulated by the miR-148/152 family, enhances Adriamycin resistance in breast cancer via upregulating the expression of drug metabolizing enzymes and drug transporter. PMID: 29743122 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 9, 2018 Category: Cancer & Oncology Authors: Chen X, Wang YW, Gao P Tags: J Exp Clin Cancer Res Source Type: research

Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study.
CONCLUSION: PLAC-B as neoadjuvant treatment of this subpopulation with TNBC and ER/PR+ patients is effective and safe. Further studies are necessitated. PMID: 29744672 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 9, 2018 Category: Cancer & Oncology Authors: Tampaki EC, Tampakis A, Alifieris CE, Krikelis D, Pazaiti A, Kontos M, Trafalis DT Tags: Clin Drug Investig Source Type: research

Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer.
CONCLUSIONS: Once-daily seviteronel was generally well tolerated in women with and 450 mg QD was chosen as the RP2D. PMID: 29744674 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 9, 2018 Category: Cancer & Oncology Authors: Bardia A, Gucalp A, DaCosta N, Gabrail N, Danso M, Ali H, Blackwell KL, Carey LA, Eisner JR, Baskin-Bey ES, Traina TA Tags: Breast Cancer Res Treat Source Type: research

Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: Position statement of the Endocrine Society of Australia, the Australian and New Zealand Bone & Mineral Society, the Australasian Menopause Society and the Clinical Oncology Society of Australia.
Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: Position statement of the Endocrine Society of Australia, the Australian and New Zealand Bone & Mineral Society, the Australasian Menopause Society and the Clinical Oncology Society of Australia. Clin Endocrinol (Oxf). 2018 May 09;: Authors: Grossmann M, Ramchand S, Milat F, Vincent A, Lim E, Kotowicz MA, Hicks J, Teede H Abstract OBJECTIVE: To formulate clinical consensus recommendations on bone health assessment and management of women with oestrogen receptor-positive ear...
Source: Clinical Breast Cancer - May 9, 2018 Category: Cancer & Oncology Authors: Grossmann M, Ramchand S, Milat F, Vincent A, Lim E, Kotowicz MA, Hicks J, Teede H Tags: Clin Endocrinol (Oxf) Source Type: research

Low Estrogen Receptor (ER)-Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy: Is Response Similar to Typical ER-Positive or ER-Negative Disease?
Abstract Objectives: Pathologic complete response (pCR) rate after neoadjuvant chemotherapy was compared between 141 estrogen receptor (ER)-negative (43%), 41 low ER+ (13%), 47 moderate ER+ (14%), and 98 high ER+ (30%) tumors. Methods: Human epidermal growth factor receptor 2-positive cases, cases without semiquantitative ER score, and patients treated with neoadjuvant endocrine therapy alone were excluded. Results: The pCR rate of low ER+ tumors was similar to the pCR rate of ER- tumors (37% and 26% for low ER and ER- respectively, P = .1722) but significantly different from the pCR rate of moderately E...
Source: Clinical Breast Cancer - May 8, 2018 Category: Cancer & Oncology Authors: Landmann A, Farrugia DJ, Zhu L, Diego EJ, Johnson RR, Soran A, Dabbs DJ, Clark BZ, Puhalla SL, Jankowitz RC, Brufsky AM, Ahrendt GM, McAuliffe PF, Bhargava R Tags: Am J Clin Pathol Source Type: research

Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial.
Abstract INTRODUCTION: The PI3K/AKT/mTOR pathway is an oncogenic driver in breast cancer (BC). In this multi-center, pre-surgical study, we evaluated the tissue effects of the AKT inhibitor MK-2206 in women with stage I-III BC. MATERIALS AND METHODS: Two doses of weekly oral MK2206 were administered at days - 9 and - 2 before surgery. The primary endpoint was reduction of pAktSer473 in breast tumor tissue from diagnostic biopsy to surgery. Secondary endpoints included changes in PI3K/AKT pathway tumor markers, tumor proliferation (ki-67), insulin growth factor pathway blood markers, pharmacokine...
Source: Clinical Breast Cancer - May 7, 2018 Category: Cancer & Oncology Authors: Kalinsky K, Sparano JA, Zhong X, Andreopoulou E, Taback B, Wiechmann L, Feldman SM, Ananthakrishnan P, Ahmad A, Cremers S, Sireci AN, Cross JR, Marks DK, Mundi P, Connolly E, Crew KD, Maurer MA, Hibshoosh H, Lee S, Hershman DL Tags: Clin Transl Oncol Source Type: research

Prognostic and clinical significance of histone deacetylase 1 expression in breast cancer: A meta-analysis.
CONCLUSION: Overall, our meta-analysis demonstrated an association between increased HDAC1 expression and better OS in Asian breast cancer patients. In addition, HDAC1 over-expression correlated with positive ER and negative HER2 expression in breast cancer. However, researches in large patients' randomised controlled trials (RCTs) are needed to confirm the results. PMID: 29738697 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 5, 2018 Category: Cancer & Oncology Authors: Qiao W, Liu H, Liu R, Liu Q, Zhang T, Guo W, Li P, Deng M Tags: Clin Chim Acta Source Type: research

Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer: a retrospective cohort analysis and literature review.
Conclusion: The results of the study confirm the high pCR rate in BRCA1-positive breast cancer after platinum-based neoadjuvant chemotherapy. Larger randomized studies and longer follow-up times are necessary to evaluate the role of platinum-based therapies in BRCA1-positive breast cancer. PMID: 29719582 [PubMed] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 4, 2018 Category: Cancer & Oncology Authors: Sæther NH, Skuja E, Irmejs A, Maksimenko J, Miklasevics E, Purkalne G, Gardovskis J Tags: Hered Cancer Clin Pract Source Type: research

miR-221 stimulates breast cancer cells and cancer-associated fibroblasts (CAFs) through selective interference with the A20/c-Rel/CTGF signaling.
CONCLUSIONS: Overall, these data provide novel insights into the stimulatory action of miR-221 in breast cancer cells and CAFs, suggesting that its inhibition may be considered toward targeted therapeutic approaches in breast cancer patients. PMID: 29716623 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 2, 2018 Category: Cancer & Oncology Authors: Santolla MF, Lappano R, Cirillo F, Rigiracciolo DC, Sebastiani A, Abonante S, Tassone P, Tagliaferri P, Di Martino MT, Maggiolini M, Vivacqua A Tags: J Exp Clin Cancer Res Source Type: research

NHERF1 and tumor microenvironment: a new scene in invasive breast carcinoma.
Abstract BACKGROUND: Tumor microenvironment (TME) includes many factors such as tumor associated inflammatory cells, vessels, and lymphocytes, as well as different signaling molecules and extracellular matrix components. These aspects can be de-regulated and consequently lead to a worsening of cancer progression. In recent years an association between the scaffolding protein Na+/H+ exchanger regulatory factor 1 (NHERF1) and tumor microenvironment changes in breast cancer (BC) has been reported. METHODS: Subcellular NHERF1 localization, vascular endothelial growth factor (VEGF), its receptor VEGFR1, hypoxia in...
Source: Clinical Breast Cancer - May 2, 2018 Category: Cancer & Oncology Authors: Saponaro C, Vagheggini A, Scarpi E, Centonze M, Catacchio I, Popescu O, Pastena MI, Giotta F, Silvestris N, Mangia A Tags: J Exp Clin Cancer Res Source Type: research

Cumulative Risk Distribution for Interval Invasive Second Breast Cancers After Negative Surveillance Mammography.
Conclusion Risk of interval invasive second breast cancer varies across women and is influenced by characteristics that can be measured at initial diagnosis, treatment, and imaging. Risk prediction models that evaluate the risk of cancers not detected by surveillance mammography should be developed to inform discussions of tailored surveillance. PMID: 29718790 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 2, 2018 Category: Cancer & Oncology Authors: Lee JM, Abraham L, Lam DL, Buist DSM, Kerlikowske K, Miglioretti DL, Houssami N, Lehman CD, Henderson LM, Hubbard RA Tags: J Clin Oncol Source Type: research

Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data.
Abstract Purpose The role of temporary ovarian suppression with gonadotropin-releasing hormone agonists (GnRHa) during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal women remains controversial. This systematic review and meta-analysis using individual patient-level data was conducted to better assess the efficacy and safety of this strategy in patients with early breast cancer. Methods The trials in which premenopausal women with early breast cancer were randomly assigned to receive (neo)adjuvant chemotherapy alone or with concurrent GnRHa were eligible for inclusion. Prima...
Source: Clinical Breast Cancer - May 2, 2018 Category: Cancer & Oncology Authors: Lambertini M, Moore HCF, Leonard RCF, Loibl S, Munster P, Bruzzone M, Boni L, Unger JM, Anderson RA, Mehta K, Minton S, Poggio F, Albain KS, Adamson DJA, Gerber B, Cripps A, Bertelli G, Seiler S, Ceppi M, Partridge AH, Del Mastro L Tags: J Clin Oncol Source Type: research

Expression and prognostic significance of ECT2 in invasive breast cancer.
Abstract AIMS: To investigate the expression of epithelial cell transforming sequence 2 (ECT2) in invasive breast cancer and its prognostic significance. METHODS: ECT2 immunohistochemical detection was performed in 165 breast cancer specimens and 100 normal control tissues. Univariable and multivariable Cox proportional hazards regression model analysis was used to confirm independent prognostic factors. The PHREG procedure linear hypotheses testing method was used to analyse survival data. RESULTS: Expression of ECT2 in breast cancer was significantly higher than that of the normal control group (p
Source: Clinical Breast Cancer - May 1, 2018 Category: Cancer & Oncology Authors: Wang HK, Liang JF, Zheng HX, Xiao H Tags: J Clin Pathol Source Type: research

Genetics and genomics of breast fibroadenomas.
Abstract Fibroadenomas of the breast are benign fibroepithelial tumours most frequently encountered in women of reproductive age, although they may be diagnosed at any age. The fibroadenoma comprises a proliferation of both stromal and epithelial components. The mechanisms underlying fibroadenoma pathogenesis remain incompletely understood. In the clinical setting, distinguishing cellular fibroadenomas from benign phyllodes tumours is a common diagnostic challenge due to subjective histopathological criteria and interobserver differences. Recent sequencing studies have demonstrated the presence of highly recurrent...
Source: Clinical Breast Cancer - May 1, 2018 Category: Cancer & Oncology Authors: Loke BN, Md Nasir ND, Thike AA, Lee JYH, Lee CS, Teh BT, Tan PH Tags: J Clin Pathol Source Type: research

Cell-free DNA integrity for the monitoring of breast cancer: Future perspectives?
Abstract Breast cancer (BC) is the most common cancer and the second cause of death in women worldwide. Therapeutic options are increasing, but the response to treatments is not always efficient and the risk of recurrence covers decades. In this perspective, the need to have a proper follow-up for the therapeutic responses and for anticipating recurrence it is urgent in the clinical setting. Liquid biopsy provides the basic principle for a non-invasive method for the routinely monitoring of BC. However, due to the heterogeneity of tumors during onset and progression, the search for tumor DNA mutations of targeted ...
Source: Clinical Breast Cancer - April 10, 2018 Category: Cancer & Oncology Authors: Sobhani N, Generali D, Zanconati F, Bortul M, Scaggiante B Tags: World J Clin Oncol Source Type: research

Clinicopathological predictors of long-term benefit in breast cancer treated with neoadjuvant chemotherapy.
Abstract AIM: To investigate the survival impact of clinicopathological factors, including pathological complete response (pCR) and tumor-infiltrating lymphocytes (sTIL) levels according to subtypes, in breast cancer (BC) patients who received neo-adjuvant chemotherapy (NAC). METHODS: We evaluated 435 BC patients who presented and received NAC at the Instituto Nacional de Enfermedades Neoplasicas from 2003 to 2014. sTIL was analyzed as the proportion of tumor stroma occupied by lymphocytes, and was prospectively evaluated on hematoxylin and eosin-stained sections of the preNAC core biopsy. pCR was considered ...
Source: Clinical Breast Cancer - April 10, 2018 Category: Cancer & Oncology Authors: Galvez M, Castaneda CA, Sanchez J, Castillo M, Rebaza LP, Calderon G, Cruz M, Cotrina JM, Abugattas J, Dunstan J, Guerra H, Mejia O, Gomez HL Tags: World J Clin Oncol Source Type: research

Women's Free-text Comments on their Quality of Life: An Exploratory Analysis from the UK Standardisation of Breast Radiotherapy (START) Trials for Early Breast Cancer.
CONCLUSIONS: Difficult personal circumstances and other health concerns affected many women's PROM ratings at 5 years of follow-up, in addition to ongoing cancer treatment effects. Greater attention to multiple sources of distress and adversity could facilitate personalised care and aid interpretation of PROMs. PMID: 29653749 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 10, 2018 Category: Cancer & Oncology Authors: Mills J, Haviland JS, Moynihan C, Bliss JM, Hopwood P, START Trial Management Group Tags: Clin Oncol (R Coll Radiol) Source Type: research

Iron-dependent cell death as executioner of cancer stem cells.
Abstract This commentary highlights the findings by Mai, et al. that ironomycin, derivatives of salinomycin, exhibited more potent and selective therapeutic activity against breast cancer stem cells by accumulating and sequestering iron in lysosome, followed by an iron-mediated lysosomal production of reactive oxygen species and an iron-dependent cell death. These unprecedented findings identified iron homeostasis and iron-mediated processes as potentially druggable in the context of cancer stem cells. PMID: 29636068 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 10, 2018 Category: Cancer & Oncology Authors: Zhao B, Li X, Wang Y, Shang P Tags: J Exp Clin Cancer Res Source Type: research

Evaluation of waiting times for breast cancer diagnosis and surgical treatment.
CONCLUSIONS: Delays in diagnosis and surgery in the case of women diagnosed on the basis of symptoms may be improved. There is a temporary tendency to a greater delay in surgery. Some clinical and biological factors must be taken into account to optimise delays. Survival results are not adversely affected by delays. PMID: 29633184 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 9, 2018 Category: Cancer & Oncology Authors: Baena-Cañada JM, Rodríguez-Pérez L, Gámez-Casado S, Quílez-Cutillas A, Cortés-Carmona C, Rosado-Varela P, Estalella-Mendoza S, Ramírez-Daffós P, Jaén-Olasolo J, Benítez-Rodríguez E Tags: Clin Transl Oncol Source Type: research

Type 1 diabetes mellitus and risk of cancer: a meta-analysis of observational studies.
Conclusion: This meta-analysis suggests that type 1 diabetes is associated with the increased risk of several types of cancer and the decreased risk of breast cancer. However, the plausible mechanisms for the decreased risk of breast cancer remain unclear. Further prospective studies with proper adjustment for possible confounding factors are warranted. PMID: 29635473 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 9, 2018 Category: Cancer & Oncology Authors: Sona MF, Myung SK, Park K, Jargalsaikhan G Tags: Jpn J Clin Oncol Source Type: research

ZMYND8 acetylation mediates HIF-dependent breast cancer progression and metastasis.
Abstract Altered epigenetic reprogramming contributes to breast cancer progression and metastasis. How the epigenetic reader mediates breast cancer progression remains poorly understood. Here, we showed that the epigenetic reader zinc finger MYND-type containing 8 (ZMYND8) is induced by HIF-1 and HIF-2 in breast cancer cells and also upregulated in human breast tumors, and is correlated with poor survival of patients with breast cancer. Genetic deletion of ZMYND8 decreases breast cancer cell colony formation, migration, and invasion in vitro, and inhibits breast tumor growth and metastasis to the lungs in mice. Th...
Source: Clinical Breast Cancer - April 9, 2018 Category: Cancer & Oncology Authors: Chen Y, Zhang B, Bao L, Jin L, Yang M, Peng Y, Kumar A, Wang JE, Wang C, Zou X, Xing C, Wang Y, Luo W Tags: J Clin Invest Source Type: research

Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update.
Abstract Purpose To provide current recommendations about fertility preservation for adults and children with cancer. Methods A systematic review of the literature published from January 2013 to March 2017 was completed using PubMed and the Cochrane Library. An Update Panel reviewed the identified publications. Results There were 61 publications identified and reviewed. None of these publications prompted a significant change in the 2013 recommendations. Recommendations Health care providers should initiate the discussion on the possibility of infertility with patients with cancer treated during their reproductive...
Source: Clinical Breast Cancer - April 5, 2018 Category: Cancer & Oncology Authors: Oktay K, Harvey BE, Partridge AH, Quinn GP, Reinecke J, Taylor HS, Wallace WH, Wang ET, Loren AW Tags: J Clin Oncol Source Type: research

Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women's Environmental Cancer and Radiation Epidemiology Study.
Conclusion Breast cancer family history confers a high CBC risk, even after excluding women with deleterious mutations. Clinicians are urged to use detailed family histories to guide treatment and future screening decisions for young women with breast cancer. PMID: 29620998 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 5, 2018 Category: Cancer & Oncology Authors: Reiner AS, Sisti J, John EM, Lynch CF, Brooks JD, Mellemkjær L, Boice JD, Knight JA, Concannon P, Capanu M, Tischkowitz M, Robson M, Liang X, Woods M, Conti DV, Duggan D, Shore R, Stram DO, Thomas DC, Malone KE, Bernstein L, WECARE Study Collaborative Gr Tags: J Clin Oncol Source Type: research

Investigation of genotoxicity risk and DNA repair capacity in breast cancer patients using anastrozole.
Abstract OBJECTIVE: Breast cancer is the most common cancer in women worldwide and the incidence increases in postmenopausal women. Anastrozole is a non-steroidal (type II), third-generation aromatase inhibitor (AI) that is used in the treatment of postmenopausal estrogen-related breast cancer. Several studies have been conducted to assess the efficacy, safety, and superiority of AIs to tamoxifen; however, a literature search did not reveal a study that investigated the genotoxic potential of AIs. The aim of this study was to investigate the possible DNA damage risk profile and individual DNA repair capacity of pa...
Source: Clinical Breast Cancer - April 4, 2018 Category: Cancer & Oncology Authors: Devecioglu TY, Aydogan F, Omurtag GZ, Bese NS, Sardas S Tags: North Clin Istanb Source Type: research

Risk factors for breast cancer among Indian women: A case-control study.
Conclusions: Waist size and WHR are the major risk factors for carcinoma of breast. Adequate exercise and weight control are the most effective lifestyle changes that can reduce the risk of developing breast cancer. PMID: 29607854 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 1, 2018 Category: Cancer & Oncology Authors: Antony MP, Surakutty B, Vasu TA, Chisthi M Tags: Niger J Clin Pract Source Type: research

Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR Study.
CONCLUSION: Weight change of> 5% during adjuvant chemotherapy in patients with high-risk early breast cancer is associated with poor OS. PMID: 29598955 [PubMed - in process] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 1, 2018 Category: Cancer & Oncology Authors: Mutschler NS, Scholz C, Friedl TWP, Zwingers T, Fasching PA, Beckmann MW, Fehm T, Mohrmann S, Salmen J, Ziegler C, Jäger B, Widschwendter P, de Gregorio N, Schochter F, Mahner S, Harbeck N, Weissenbacher T, Jückstock J, Janni W, Rack B Tags: Clin Breast Cancer Source Type: research

Granular cell tumor in axillary region: A rare entity.
vá I Abstract A granular cell tumor (GCT), is a rare soft tissue tumor which may occur throughout the body, usually in the head and neck, skin or subcutaneous tissues of the trunk and upper extremities, and female genital region. A total of 5-8% of all cases of GCTs occur in the breast. GCT of the breast may mimic breast cancer both clinically and radiologically. GCTs are usually benign and solitary; however, approximately 2% occur as malignant tumors. Benign GCTs are treated with wide local excision and are associated with a good prognosis. The current case report presents findings in a patient with a beni...
Source: Clinical Breast Cancer - March 16, 2018 Category: Cancer & Oncology Authors: Pohlodek K, Jáni P, Mečiarová I Tags: Mol Clin Oncol Source Type: research

Baseline neutrophil-to-lymphocyte ratio predicts the prognosis of castration-resistant prostate cancer treated with abiraterone acetate.
Abstract Abiraterone acetate (AA), a CYP17 inhibitor, now has a crucial role in the treatment of castration-resistant prostate cancer (CRPC), and previous studies have reported several prognostic clinical factors for AA treatment. The neutrophil-to-lymphocyte ratio (NLR) has also been investigated for a CRPC treatments in a few reports, however it has not been identified to be a prognostic factor for AA treatment in Japanese patients. The present study aimed to assess the association of the baseline NLR with the overall survival (OS) in CPRC patients treated by AA. The present study retrospectively reviewed a tota...
Source: Clinical Breast Cancer - March 16, 2018 Category: Cancer & Oncology Authors: Yasui M, Hasegawa Y, Kawahara T, Kumano Y, Miyoshi Y, Matsubara N, Uemura H Tags: Mol Clin Oncol Source Type: research

Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44).
Conclusion pCR correlated with long-term outcome. In patients with hormone receptor-positive tumors, prolonged anti-HER2 treatment-neoadjuvant lapatinib for 6 months, followed by adjuvant trastuzumab for 12 months-significantly improved survival compared with anti-HER2 treatment with trastuzumab alone. PMID: 29543566 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 15, 2018 Category: Cancer & Oncology Authors: Untch M, von Minckwitz G, Gerber B, Schem C, Rezai M, Fasching PA, Tesch H, Eggemann H, Hanusch C, Huober J, Solbach C, Jackisch C, Kunz G, Blohmer JU, Hauschild M, Fehm T, Nekljudova V, Loibl S, GBG and the AGO-B Study Group Tags: J Clin Oncol Source Type: research

Risk and Prognosis of Cancer After Lower Limb Arterial Thrombosis.
Conclusions -Lower limb arterial thrombosis was a marker of occult cancer, especially lung cancer, and was an adverse prognostic factor for mortality in common cancers. PMID: 29540440 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 14, 2018 Category: Cancer & Oncology Authors: Sundbøll J, Veres K, Horváth-Puhó E, Adelborg K, Sørensen HT Tags: Circulation Source Type: research

p95HER2 methionine 611 carboxy-terminal fragment is predictive of trastuzumab adjuvant treatment benefit in the FinHer trial.
CONCLUSIONS: p95 expression levels were prognostic in the chemotherapy-alone arm and predictive of trastuzumab treatment benefit in FinHer. These results warrant further investigation of p95 as a predictive marker of trastuzumab treatment benefit in the adjuvant setting. PMID: 29535130 [PubMed - as supplied by publisher] (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - March 13, 2018 Category: Cancer & Oncology Authors: Sperinde J, Huang W, Vehtari A, Chenna A, Kellokumpu-Lehtinen PL, Winslow J, Bono P, Lie Y, Petropoulos CJ, Weidler JM, Joensuu H Tags: Clin Cancer Res Source Type: research

Breast cancer histologic grading using digital microscopy: concordance and outcome association.
This study aims at investigating the agreement between BC grading using traditional light microscopy (LM) and digital WSI with consideration of reproducibility and impact on outcome prediction. METHODS: A large (n=1675) well-characterised cohort of BC originally graded by LM was re-graded using WSI. Two separate virtual-based grading sessions (V1 and V2) were performed with a 3-month washout period. Outcome was assessed using BC-specific and distant metastasis-free survival. RESULTS: The concordance between LM grading and WSI was strong (LM/WSI Cramer's V: V1=0.576, and V2=0.579). The agreement regarding grade co...
Source: Clinical Breast Cancer - March 13, 2018 Category: Cancer & Oncology Authors: Rakha EA, Aleskandarani M, Toss MS, Green AR, Ball G, Ellis IO, Dalton LW Tags: J Clin Pathol Source Type: research

Comparative analysis of the effect of different radiotherapy regimes on lymphocyte and its subpopulations in breast cancer patients.
Abstract PURPOSE: The aim of this study was to determine whether different radiotherapy (RT) fractionation schemes induce disparate effects on lymphocyte and its subsets in breast cancer patients. METHODS: 60 female patients diagnosed with breast cancer were recruited in this study after receiving modified radical mastectomy and were randomly divided into two groups. One group received irradiation at a standard dose of 50 Gy in 25 fractions and the other at a dose of 40.3 Gy in 13 fractions. Both total lymphocyte count and its composition were recorded at three timepoints: right before the radiation...
Source: Clinical Breast Cancer - March 13, 2018 Category: Cancer & Oncology Authors: Yuan C, Wang Q Tags: Clin Transl Oncol Source Type: research

Synchronous Detection of Male Breast Cancer and Prostatic Cancer in a Patient With Suspected Prostatic Carcinoma on 68Ga-PSMA PET/CT Imaging.
We report a case of 64-year-old man who presented with the history of lower urinary tract symptoms. The digital rectal examination revealed hard and nodular prostate, and serum prostate-specific antigen level was 23.4 ng/mL. Ga-labeled prostate-specific membrane antigen PET/CT revealed prostate-specific membrane antigen-expressing lesions in the prostate, axillary tail of the right breast, and axillary lymph nodes. Histology from prostate revealed prostate carcinoma, whereas fine-needle aspiration from the breast revealed invasive ductal carcinoma of the breast. PMID: 29538032 [PubMed - as supplied by publisher] (Sour...
Source: Clinical Breast Cancer - March 13, 2018 Category: Cancer & Oncology Authors: Kumar R, Mittal BR, Bhattacharya A, Singh H, Singh SK Tags: Clin Nucl Med Source Type: research

Telocytes in the female reproductive system: An overview of up-to-date knowledge.
Abstract Telocytes are emerging cell population localized in the stroma of numerous organs, characterized by a distinctive morphology - small cell body with very long, slender prolongations, termed telopodes. Those cells can be found in the whole female reproductive system: in the vagina, uterus, oviducts and ovaries, mammary glands and also in the placenta. In our review, we aim at complete and transparent revision of the current knowledge of telocytes' localization and function, enriched by the analysis of the possible future direction of development of their clinical applications. The function of telocytes in t...
Source: Clinical Breast Cancer - March 13, 2018 Category: Cancer & Oncology Authors: Janas P, Kucybała I, Radoń-Pokracka M, Huras H Tags: Adv Clin Exp Med Source Type: research